246 related articles for article (PubMed ID: 16915233)
1. Can open-source R&D reinvigorate drug research?
Munos B
Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
[TBL] [Abstract][Full Text] [Related]
2. Trends in development and approval times for new therapeutics in the United States.
Reichert JM
Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
[TBL] [Abstract][Full Text] [Related]
3. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
4. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
5. The critical path to medical innovation.
Williams D
Med Device Technol; 2004 Jun; 15(5):8-10. PubMed ID: 15285478
[TBL] [Abstract][Full Text] [Related]
6. Progress in standards for reporting omics data.
Taylor CF
Curr Opin Drug Discov Devel; 2007 May; 10(3):254-63. PubMed ID: 17554851
[TBL] [Abstract][Full Text] [Related]
7. Carlo Incerti.
Incerti C
Nat Rev Drug Discov; 2008 Aug; 7(8):638. PubMed ID: 18670428
[No Abstract] [Full Text] [Related]
8. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
9. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
10. Benefit the patient, manage the risk: a system goal.
Califf RM
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):269-76. PubMed ID: 15133777
[No Abstract] [Full Text] [Related]
11. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
Grabowski H
Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
[TBL] [Abstract][Full Text] [Related]
12. Virtual drug discovery and development for neglected diseases through public-private partnerships.
Nwaka S; Ridley RG
Nat Rev Drug Discov; 2003 Nov; 2(11):919-28. PubMed ID: 14668812
[No Abstract] [Full Text] [Related]
13. [Drug development--from receptor research to therapy].
Lammintausta R; Scheinin M
Duodecim; 1998; 114(10):957-66. PubMed ID: 11524784
[No Abstract] [Full Text] [Related]
14. Helping science to succeed: improving processes in R&D.
Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
[TBL] [Abstract][Full Text] [Related]
15. Competitive Workflow: novel software architecture for automating drug design.
Cartmell J; Krstajic D; Leahy DE
Curr Opin Drug Discov Devel; 2007 May; 10(3):347-52. PubMed ID: 17554862
[TBL] [Abstract][Full Text] [Related]
16. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
Alavijeh MS; Palmer AM
IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
[TBL] [Abstract][Full Text] [Related]
17. Growing pains in AIDS drug development.
Herrera S
Nat Biotechnol; 2004 Oct; 22(10):1194. PubMed ID: 15470440
[No Abstract] [Full Text] [Related]
18. Ligand-based vascular targeting of disease.
Rybak JN; Trachsel E; Scheuermann J; Neri D
ChemMedChem; 2007 Jan; 2(1):22-40. PubMed ID: 17154429
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Identifying quality leads - an important factor in reducing attrition of clinical candidates.
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):381-2. PubMed ID: 17659478
[No Abstract] [Full Text] [Related]
[Next] [New Search]
